| 药品通用名/英文 |
NDC号/批准号 |
商标名 |
成份名 |
剂型 |
公司/生产厂 |
上市国/产地 |
规格/包装规格 |
备注 |
操作 |
| 阿帕他胺片（阿帕鲁胺片) |
注册证号 H20190050 |
安森珂/ERLEADA |
Apalutamide |
片剂 |
Janssen-Cilag International NV/Janssen Ortho, LLC |
中国/美国 |
60mg*120片/瓶/盒 |
|
请先登录 |
| 阿帕鲁胺片 |
HK-66016 |
ERLEADA |
apalutamide |
tablet |
JOHNSON & JOHNSON (HONG KONG) LTD. |
Hong Kong |
60mg |
|
请先登录 |
| 阿帕鲁胺片 |
|
Erleada |
apalutamide |
tablet |
Janssen-Cilag International N.V./Janssen Cilag SpA |
Belgique/Italy |
60 mg*120 Tablets/bottle |
|
请先登录 |
| 阿帕鲁胺片 |
|
Erleada |
apalutamide |
tablet |
Janssen-Cilag International N.V./Janssen Cilag SpA |
Belgique/Italy |
60 mg*120 Tablets/box |
|
请先登录 |
| 阿帕他胺片（阿帕鲁胺片) |
|
Erleada |
apalutamide |
tablet |
Janssen-Cilag International N.V./Janssen Cilag SpA |
Belgique/Italy |
60 mg*112Tablets/box |
|
请先登录 |
| 阿帕鲁胺片 |
|
Erleada |
apalutamide |
tablet |
Janssen-Cilag Ltd/Janssen Cilag SpA |
UK/Italy |
60 mg*120 Tablets/bottle，120 Tablets/box，112Tablets/box |
|
请先登录 |
| 阿帕鲁胺片 |
|
Erleada |
apalutamide |
tablet |
Janssen-Cilag GmbH/Janssen Cilag SpA |
Germany/Italy |
60 mg*120 Tablets/bottle，120 Tablets/box，112Tablets/box |
|
请先登录 |
| 阿帕鲁胺片 |
|
Erleada |
apalutamide |
tablet |
Janssen-Cilag/Janssen Cilag SpA |
France/ Italy |
60 mg*120 Tablets/bottle，120 Tablets/box，112Tablets/box |
|
请先登录 |
| 注射用西米普利单抗 |
61755-008-01 |
Libtayo |
cemiplimab-rwlc |
injection |
Regeneron Pharmaceuticals, Inc. |
USA |
350 mg/7 mL (50 mg/mL)/vial/box |
|
请先登录 |
| 注射用西米普利单抗 |
|
Libtayo |
cemiplimab-rwlc |
injection |
sanofi-aventis Ireland Ltd. T/A SANOFI/Regeneron Ireland DAC |
Ireland |
350 mg/7 mL (50 mg/mL)/vial/box |
|
请先登录 |
| 注射用西米普利单抗 |
|
Libtayo |
cemiplimab-rwlc |
injection |
Sanofi Belgium/Regeneron Ireland Unlimited Company |
Belgium/Ireland |
350 mg/7 mL (50 mg/mL)/vial/box |
|
请先登录 |
| 注射用西米普利单抗 |
|
Libtayo |
cemiplimab-rwlc |
injection |
Sanofi/Regeneron Ireland DAC |
UK/Ireland |
350 mg/7 mL (50 mg/mL)/vial/box |
|
请先登录 |
| 注射用西米普利单抗 |
|
Libtayo |
cemiplimab-rwlc |
injection |
sanofi-aventis France/Regeneron Ireland Unlimited Company |
FRANCE/Irlande |
350 mg/7 mL (50 mg/mL)/vial/box |
|
请先登录 |
| 注射用西米普利单抗 |
|
Libtayo |
cemiplimab-rwlc |
injection |
Sanofi-Aventis Deutschland GmbH/Regeneron Ireland Unlimited Company |
Germany/Irlande |
350 mg/7 mL (50 mg/mL)/vial/box |
|
请先登录 |
| 洛拉替尼片 |
0069-0227-01 |
Lorbrena |
lorlatinib |
tablet |
PFIZER LABORATORIES DIV PFIZER INC |
USA |
25 mg*30tablet/BOTTLE |
|
请先登录 |
| 洛拉替尼片 |
0069-0231-01 |
Lorbrena |
lorlatinib |
tablet |
PFIZER LABORATORIES DIV PFIZER INC |
USA |
100 mg*30tablet/BOTTLE |
|
请先登录 |
| 洛拉替尼片 |
|
Lorbrena |
lorlatinib |
tablet |
ファイザー株式会社 |
JP |
25 mg*40tablet/box |
|
请先登录 |
| 洛拉替尼片 |
|
Lorviqua |
lorlatinib |
tablet |
ファイザー株式会社 |
JP |
100 mg*10tablet/box |
|
请先登录 |
| 洛拉替尼片 |
|
Lorviqua |
lorlatinib |
tablet |
Pfizer Europe MA EEIG/Pfizer Manufacturing Deutschland GmbH |
UK/Germany |
25 mg*4010,90,120tablet/box |
|
请先登录 |
| 洛拉替尼片 |
|
Lorviqua |
lorlatinib |
tablet |
Pfizer Europe MA EEIG/Pfizer Manufacturing Deutschland GmbH |
UK/Germany |
100 mg*30tablet/box |
|
请先登录 |
| 洛拉替尼片 |
HK-66411 |
LORVIQUA |
lorlatinib |
tablet |
PFIZER CORPORATION HONG KONG LIMITED |
HONG KONG |
100 mg |
|
请先登录 |
| 洛拉替尼片 |
HK-66412 |
LORVIQUA |
lorlatinib |
tablet |
PFIZER CORPORATION HONG KONG LIMITED |
HONG KONG |
25 mg |
|
请先登录 |
| 注射用帕西妥莫单抗-TDFK |
0310-4715-11 |
LUMOXITI |
moxetumomab pasudotox |
injection |
AstraZeneca Pharmaceuticals LP,/ AstraZeneca AB |
USA/Sweden |
6.5mg/1ml/vial/box |
|
请先登录 |
| 注射用 莫单抗-TDFK |
0310-4700-01 |
LUMOXITI |
moxetumomab pasudotox |
injection |
AstraZeneca Pharmaceuticals LP,/ AstraZeneca AB |
USA/Sweden |
1mg/1ml/vial/box |
|
请先登录 |
| 注射用奥索瑞肽镥[177Lu] |
69488-003-01 |
LUTATHERA |
lutetium lu 177 dotatate |
injection |
Advanced Accelerator Applications USA, Inc/Advanced Accelerator Applications, S.r.l. （Advanced Accelerator Applications USA, Inc. ) |
USA/ Italy(USA) |
（10 mCi/ 1 mL）/20.5ML/VIAL |
|
请先登录 |
| 注射用奥索瑞肽镥[178Lu] |
|
LUTATHERA |
lutetium lu 177 dotatate |
injection |
ADVANCED ACCELERATOR APPLICATIONS
|
Italy |
（370 MBQ/ML）/20.5ML/VIAL，25ml/vial |
|
请先登录 |
| 注射用莫格利珠单抗-KPKC |
42747-761-01 |
POTELIGEO |
MOGAMULIZUMAB-KPKC |
injection |
KYOWA KIRIN /Kyowa Kirin, Inc. |
USA |
20 mg/5 mL(4 mg/mL)/vial/box |
|
请先登录 |
| 注射用莫格利珠单抗-KPKC |
|
POTELIGEO |
MOGAMULIZUMAB-KPKC |
injection |
Kyowa Kirin Holdings B.V./Piramal Healthcare UK Limited |
Nederland /UK |
20 mg/5 mL(5 mg/mL)/vial/box |
|
请先登录 |
| 注射用莫格利珠单抗-KPKC |
|
POTELIGEO |
Mogamulizumab |
injection |
協和キリン株式会社 |
JP |
20mg/vial/bottle |
|
请先登录 |
| 甲苯磺他拉唑帕利胶囊 |
0069-0296-30 |
Talzenna |
talazoparib |
capsule |
PFIZER LABORATORIES DIV PFIZER INC |
USA |
0.25 mg*30CAP/BOTTLE |
|
请先登录 |
400-8577-888